Global Glucagon-like Peptide 1 (GLP-1) Market: Size, Trends COVID-19 Impact and Forecast up to 2027

DELHI, India - Jan. 12, 2023 - PRLog -- GLP-1 receptor agonists are a type of non-insulin medication used to treat type 2 diabetes in conjunction with diet and exercise. These medications are used to help lower blood glucose levels and hemoglobin A1C, as well as to aid in weight loss. GLP-1 signals the hypothalamus, the part of the brain in charge of appetite and thirst, to consume less water and food. In 2021, the global glucagon-like peptide 1 (GLP-1) market was valued at US$16.53 billion, and is probable to reach US$24.10 billion by 2027.

Scope of the Report

-- An in-depth analysis of the global glucagon-like peptide 1 (GLP-1) market by value, by product, by route of administration, by region, etc.

-- The regional analysis of the glucagon-like peptide 1 (GLP-1) market, including the following regions:

North America (The US, Canada and Mexico)
Asia Pacific (China, Japan, India, Australia South Korea and Rest of Asia Pacific)
Europe (Germany, UK, Spain, Italy, France and Rest of Europe)
Latin America
Middle East and Africa

-- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

-- Provides an analysis of the COVID-19 impact on the global glucagon-like peptide 1 (GLP-1) market, with post COVID impact analysis.

-- Evaluation of the potential role of glucagon-like peptide 1 (GLP-1) to improve the market status.

-- Identification of new technological developments, R&D activities, and collaborations occurring in the glucagon-like peptide 1 (GLP-1) market.

-- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

-- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

-- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.

For further details, kindly visit :

https://www.daedal-research.com/pharma-healthcare/global-glucagon-like-peptide-1-glp-1-market-size-and-trends-with-impact-of-covid-19-and-forecast-up-to-2027

Rajeev Kumar

(Business Development Manager)

Address:  36 SFS Flats

Paschim Vihar

New Delhi-110063

Mobile: +91-9811715635

Tel: +91-120-4553017

Mail ID - info@daedal-research.com